Program
fosmanogepix
Also written as “Fosmanogepix”, “APX001” and “Fosmanogepix IV infusion”.
Its studies are mostly in Mycoses · Candidemia · Invasive Fungal Infections, led by Basilea Pharmaceutica.
Furthest: phase 3, since Jun 7, 202213 company-led studies, 3 open or runningNext primary completion: Mar 9, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Basilea Pharmaceutica | 133 open or running | phase 3since Jun 7, 2022 | Nov 1, 2016 | Mar 9, 2027phase 1 · NCT07881224 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 1, 2016First studies: 2 phase 1 studies in MycosesFirst studyNCT02957929, NCT02956499
- Jul 19, 2018Phase 2 study in CandidemiaNCT03604705 · 21 enrolled · United States, Belgium, Germany and more
- Oct 30, 2019Phase 2 study in CandidemiaNCT04148287 · 9 enrolled · South Africa
- Nov 12, 2019Phase 1 study in MycosesNCT04166669 · 36 enrolled · Netherlands
- Jan 22, 2020Phase 2 study in Invasive Fungal InfectionsNCT04240886 · 21 enrolled · United States, Belgium, Germany and more
- Oct 1, 2020Phase 1 study in MycosesNCT04804059 · 10 enrolled · United Kingdom
- Jun 7, 2022Phase 3 study in CandidemiaNCT05421858 · 450 planned · United States, Argentina, Australia and more
- Aug 4, 2022Phase 1 study in Invasive Fungal InfectionsNCT05491733 · 18 enrolled · United States
- Oct 12, 2022Phase 1 study in Hepatic ImpairmentNCT05582187 · 28 enrolled · United States
- Mar 27, 2025Phase 3 study in MycosesNCT06925321 · 234 planned · United States, Australia, Austria and more
- Apr 24, 2025Phase 1 study in HealthyNCT06961708 · 54 enrolled · China
- Oct 12, 2026Phase 1 study in Healthy Adult ParticipantsNCT07881224 · 42 planned · Netherlands
Ahead
- Mar 9, 2027Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07881224
- Jan 30, 2028Primary completion: phase 3 study in CandidemiaNCT05421858
- Feb 2028Primary completion: phase 3 study in MycosesNCT06925321
TargetBeta
PIGW →read by rule
“An orally available small molecule inhibitor of the Gwt1 fungal enzyme ”NCIt, by rule
“GPI-anchored wall transfer protein 1 inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07881224Healthy Adult Participants · Netherlands | 1 | Recruiting | Mar 9, 2027 | 42 |
| NCT06961708Healthy · China | 1 | Completed | Jul 15, 2025 | 54 |
| NCT06925321Mycoses · United States, Australia, Austria and more | 3 | Recruiting | Feb 2028 | 234 |
| NCT05582187Hepatic Impairment · United States | 1 | Completed | Oct 16, 2025 | 28 |
| NCT05491733Invasive Fungal Infections · United States | 1 | Completed | May 13, 2021 | 18 |
| NCT05421858Candidemia · United States, Argentina, Australia and more | 3 | Recruiting | Jan 30, 2028 | 450 |
| NCT04804059Mycoses · United Kingdom | 1 | Completed | Sep 26, 2018 | 10 |
| NCT04240886Invasive Fungal Infections · United States, Belgium, Germany and more | 2 | Terminated | Mar 29, 2022 | 21 |
| NCT04166669Mycoses · Netherlands | 1 | Completed | Mar 3, 2020 | 36 |
| NCT04148287Candidemia · South Africa | 2 | Completed | Nov 30, 2020 | 9 |
| NCT03604705Candidemia · United States, Belgium, Germany and more | 2 | Completed | Mar 31, 2020 | 21 |
| NCT02957929Mycoses · Netherlands | 1 | Completed | Apr 20, 2017 | 46 |
| NCT02956499Mycoses · Netherlands | 1 | Completed | Jul 3, 2017 | 200 |
How it is read
Names in the registry
- “Fosmanogepix”, 4 entries
- “APX001”, 4 entries
- “Fosmanogepix IV infusion”, 1 entry
- “Fosmanogepix oral tablet”, 1 entry
- “Oral Fosmanogepix”, 1 entry
Conditions, from the studies’ own filings
- Mycoses, 5 studies
- Candidemia, 3 studies
- Invasive Fungal Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.